CoRegen, a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, announced the close of a $93,390,000 million financing.

CoRegen是一家致力于为受一些最具侵袭性癌症影响的患者寻找新疗法的生物制药公司，宣布完成了9339万美元的融资。

The proceeds from this round will be used to advance CoRegen's chemistry, manufacturing, and controls (CMC) development, initiate a Phase 1/2 clinical trial for its steroid receptor coactivator 3 knock-out Regulatory T (Treg) cells (SRC3-KO) program in patients with various solid-tumor types in the first half of 2026 and expand its leadership team with key hires to drive execution and support the company's growth..

本轮收益将用于推动CoRegen的化学、制造和控制（CMC）开发，于2026年上半年启动其类固醇受体共激活因子3敲除调节性T细胞（SRC3-KO）项目针对多种实体瘤患者的1/2期临床试验，并通过关键职位的招聘扩大其领导团队，以推动执行并支持公司的增长。